-

Shareholder Alert: Robbins LLP Announces It Is Investigating Allakos, Inc. (ALLK) for Misleading Shareholders

SAN DIEGO & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating Allakos, Inc. (NYSE: ALLK) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. Allakos is a clinical stage biopharmaceutical company that focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases.

If you suffered a loss as a result of Allakos' misconduct, click here.

Allakos, Inc. (ALLK) Accused of Releasing Compromised Trial Results

On August 5, 2019, Allakos announced that its drug AK002 had met all pre-specified primary and secondary endpoints in its Phase 2 clinical trial (the "ENIGMA Trial"). Then, on December 18, 2019, Seligman Investments published a report identifying several concerns with the ENIGMA trial, including but not limited to "flagrant nepotism in key clinical roles," "poor controls as well as Allakos' role in running the study itself," and trial results that were compromised by ample use of steroids, glaring omissions, cherry-picked measures, and statistical gimmicks and obfuscation. Since this news, shares of Allakos have precipitously declined and currently trade at around $55.00, representing a 60% decline from its class period high of $137.73.

Allakos, Inc. (ALLK) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

 

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:ALLK

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Simulation Plus, Inc. (NASDAQ: SLP) Investors Should Contact Robbins LLP for Information About Investigation

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP announces that it is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain officers and directors violated securities laws or breached fiduciary duties owed to shareholdersThe investigation concerns whether Simulation Plus made materially false or misleading statements or omitted material information regarding its financial reporting, internal controls, and business outlook.Investors who purchased Simulation Plus securities and suf...

Acadia Healthcare (NASDAQ: ACHC) Investors: Court Denies Motion to Dismiss Paving Way for Litigation to Proceed; Contact Robbins LLP for Information About Your Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors of their rights following the court's decision to allow securities claims against Acadia Healthcare Company (NASDAQ: ACHC) to proceed.The case is continuing after the Court denied defendants’ motion to dismiss the amended complaint. The ruling means the case can proceed past the motion-to-dismiss stage. It does not determine whether the allegations are true or establish liability. Investors who purchased or otherwise acquired Acadia Healt...

Insulet Corporation (NASDAQ: PODD) Investors Who Suffered Losses May Be Eligible to Participate in Securities Class Action; Contact Robbins LLP for Information About Recovering Your Losses

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026, inclusive (the "Class Period"). The lawsuit alleges that Insulet made materially false or misleading statements regarding its manufacturing controls and the safety and reliability of its insulin delivery products. Investors who su...
Back to Newsroom